Literature DB >> 28566936

Interaction of Serum Phosphate with Age as Predictors of Cardiovascular Risk Scores in Stable Renal Transplant Recipients.

Jillian Kerry1, Holly Mansell2, Hamdi Elmoselhi3, Mike Moser1,3, Ahmed Shoker3.   

Abstract

We calculated rate of changes in the cardiovascular risk calculator for renal transplant recipients (CRCRTR) major adverse cardiac events (MACE) in clinically stable renal transplant recipients (RTRs) to identify covariables that associate with fast cardiovascular (CV) risk progression. CRCRTR-MACE scores were calculated on 139 patients in 2011 and 2014. Score changes above and below median changes in scores were labeled fast or slow CV risk progression. Multivariate analysis (MVA) was performed to identify variables significant to percentage changes in scores. Receiver-operating characteristic (ROC) analysis was performed to define sensitivity and specificity of factors significant to fast score progression. Follow-up was 2.61 (2.02-4.47) years. Slow and fast progressions were present in 50.4 and 49.6% of patients, with a median change of 25.8% (- 92.1 to 1,444.7%). MVA showed percentage changes in age and serum phosphate were the only significant variables impacting fast progression in scores. ROC showed 2011 serum phosphate of 1.15 mmol/L to predict fast progression (area under the curve [AUC] of 0.628, p > 0.0126). Age older than 45 years combined with 2011 serum phosphate above 1.15 mmol/L had a significant AUC of 0.781, p < 0.0010 interleukin (IL)-1A and IL-28A were significant associates with serum phosphate above 1.1 mmol/L in the MVA. Changes in CV risk in RTR over time are highly variable. Serum phosphate, even within upper normal levels, predicts worsening of CV risk scores in stable RTR.

Entities:  

Keywords:  cardiovascular disease; cardiovascular risk calculator for renal transplant recipients; cardiovascular risk factors; glomerular filtration rate; phosphorous; renal function; renal transplant

Year:  2016        PMID: 28566936      PMCID: PMC5446254          DOI: 10.1055/s-0036-1593827

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  35 in total

Review 1.  Epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

2.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 3.  Phosphate is a vascular toxin.

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-11-17       Impact factor: 3.714

4.  Serum phosphorus levels associate with coronary atherosclerosis in young adults.

Authors:  Robert N Foley; Allan J Collins; Charles A Herzog; Areef Ishani; Philip A Kalra
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

Review 5.  Vascular calcification: in vitro evidence for the role of inorganic phosphate.

Authors:  Cecilia M Giachelli
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

Review 6.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

Review 7.  Phosphorus and the kidney: What is known and what is needed.

Authors:  Girish N Nadkarni; Jaime Uribarri
Journal:  Adv Nutr       Date:  2014-01-01       Impact factor: 8.701

Review 8.  Phosphate levels and cardiovascular disease in the general population.

Authors:  Robert N Foley
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

9.  Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited.

Authors:  Bryce Kiberd; Romuald Panek
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

10.  Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: results from the National Health and Nutrition Examination Survey (NHANES): 2005-2010.

Authors:  Janet M Wojcicki
Journal:  BMC Nephrol       Date:  2013-08-21       Impact factor: 2.388

View more
  2 in total

Review 1.  The guiding role of bone metabolism test in osteoporosis treatment.

Authors:  Wei Zhang; Guo-Ji Yang; Shi-Xian Wu; Dong-Qing Li; Ying-Bo Xu; Cheng-Hong Ma; Jun-Ling Wang; Wei-Wen Chen
Journal:  Am J Clin Exp Immunol       Date:  2018-04-05

Review 2.  Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.

Authors:  Sophie Liabeuf; Lynda Cheddani; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2018-06-05       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.